Elicio Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Elicio Therapeutics
ELTX Stock   8.17  0.48  6.24%   
Elicio Therapeutics financial statements provide useful quarterly and yearly information to potential Elicio Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Elicio Therapeutics financial statements helps investors assess Elicio Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Elicio Therapeutics' valuation are summarized below:
Market Capitalization
98.5 M
Earnings Share
(3.44)
We have found one hundred twenty available fundamental signals for Elicio Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Elicio Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 39.8 M in 2025. Enterprise Value is likely to rise to about 34.2 M in 2025
Check Elicio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elicio Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 450.4 K, Depreciation And Amortization of 828.2 K or Selling General Administrative of 14.4 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 3.5. Elicio financial statements analysis is a perfect complement when working with Elicio Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Elicio Therapeutics Correlation against competitors.
For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Elicio Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets20.5 M31.2 M14 M
Slightly volatile
Short and Long Term Debt Total6.1 M8 M3.1 M
Slightly volatile
Other Current Liabilities3 M4.4 M2 M
Slightly volatile
Total Current Liabilities8.9 M11.2 M4.8 M
Slightly volatile
Property Plant And Equipment Net4.2 M8.4 M2.8 M
Slightly volatile
Accounts Payable5.3 M5 M1.6 M
Slightly volatile
Cash11 M14.8 M8.6 M
Slightly volatile
Non Current Assets Total7.3 M12.4 M4.2 M
Slightly volatile
Cash And Short Term Investments11 M14.8 M8.6 M
Slightly volatile
Net Receivables880.6 K926.9 K851.6 K
Slightly volatile
Common Stock Shares Outstanding4.4 M4.6 M6.9 M
Slightly volatile
Liabilities And Stockholders Equity20.5 M31.2 M14 M
Slightly volatile
Non Current Liabilities Total5.1 M5.4 M43.1 M
Pretty Stable
Other Current Assets4.2 M4 M1 M
Slightly volatile
Other Stockholder Equity133.6 M176.7 M58.5 M
Slightly volatile
Total Liabilities17.2 M18.1 M48.2 M
Very volatile
Property Plant And Equipment Gross5.1 M9.8 M3.3 M
Slightly volatile
Total Current Assets13.2 M18.8 M9.8 M
Slightly volatile
Capital Stock135.2 K110.4 K76.1 K
Slightly volatile
Short Term Debt994.2 K1 M1.3 M
Pretty Stable
Common Stock135.2 K110.4 K76.1 K
Slightly volatile
Property Plant Equipment10.3 M9.8 M3.3 M
Slightly volatile
Other Liabilities67 K105.8 K44.6 K
Slightly volatile
Short and Long Term Debt9.4 M10.6 M11.6 M
Slightly volatile
Non Current Liabilities Other67 K105.8 K44.6 K
Slightly volatile

Elicio Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income450.4 K428.9 K134 K
Slightly volatile
Depreciation And Amortization828.2 K1.3 M432.1 K
Slightly volatile
Selling General Administrative14.4 M13.7 M5.3 M
Slightly volatile
Other Operating Expenses24.9 M41.1 M18.1 M
Slightly volatile
Research Development17.8 M26.1 M13.2 M
Slightly volatile
Total Operating Expenses24.6 M39.8 M18 M
Slightly volatile
Reconciled Depreciation1.4 M1.3 M365.4 K
Slightly volatile
Income Tax Expense4.3 M4.1 M1.1 M
Slightly volatile
Cost Of Revenue1.1 M1.1 M1.6 M
Slightly volatile
Interest Expense2 M1.2 M1.2 M
Slightly volatile

Elicio Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings11.7 M13.2 M14.4 M
Slightly volatile
Stock Based Compensation1.4 M1.4 M431.9 K
Slightly volatile
Begin Period Cash Flow8.1 M7.6 M9.9 M
Slightly volatile
Other Cashflows From Financing Activities17.5 M25 M11.2 M
Slightly volatile
Depreciation1.4 M1.3 M365.4 K
Slightly volatile
Other Non Cash Items228.3 K240.3 K323.2 K
Slightly volatile
Capital Expenditures56.4 K59.4 K403.2 K
Slightly volatile
Issuance Of Capital Stock10.3 M6.3 M8.6 M
Slightly volatile
Total Cash From Financing Activities24.3 M44.4 M14.7 M
Slightly volatile
End Period Cash Flow12 M16.4 M9 M
Slightly volatile
Change To Netincome6.2 M5.9 M1.6 M
Slightly volatile
Change To Account Receivables352 K396 K431.8 K
Slightly volatile
Other Cashflows From Investing Activities27.2 K30.6 K33.4 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.570.64.6056
Pretty Stable
Days Sales Outstanding10.5911.1514.5438
Slightly volatile
Average Payables1.6 M2 M1.8 M
Slightly volatile
Stock Based Compensation To Revenue0.02380.02510.0747
Slightly volatile
Capex To Depreciation0.04820.05082.0238
Very volatile
Payables Turnover0.290.319.1086
Slightly volatile
Sales General And Administrative To Revenue0.290.311.3287
Slightly volatile
Research And Ddevelopement To Revenue0.540.571.5825
Pretty Stable
Capex To Revenue0.01590.01670.1346
Pretty Stable
Cash Per Share2.792.9367.7325
Slightly volatile
Days Payables Outstanding1.3 K1.2 K530
Slightly volatile
Income Quality1.551.071.4036
Slightly volatile
Current Ratio2.781.932.6666
Very volatile
Receivables Turnover17.0133.8929.9195
Slightly volatile
Graham Number20.5121.58189
Slightly volatile
Capex Per Share0.01430.0151.692
Slightly volatile
Revenue Per Share9.6710.17294
Slightly volatile
Interest Debt Per Share1.721.81234
Slightly volatile
Debt To Assets0.390.290.2896
Pretty Stable
Days Of Payables Outstanding1.3 K1.2 K530
Slightly volatile
Long Term Debt To Capitalization0.790.68950.7147
Very volatile
Quick Ratio2.981.932.768
Very volatile
Net Income Per E B T0.250.330.3354
Slightly volatile
Cash Ratio2.431.522.3772
Very volatile
Days Of Sales Outstanding10.5911.1514.5438
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.90.9967
Pretty Stable
Fixed Asset Turnover30.0528.6210.4689
Slightly volatile
Debt Ratio0.390.290.2896
Pretty Stable
Price Sales Ratio0.570.64.6056
Pretty Stable
Asset Turnover1.811.720.8071
Slightly volatile
Gross Profit Margin0.460.860.7081
Pretty Stable

Elicio Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap39.8 M38 M23.5 M
Slightly volatile

Elicio Fundamental Market Drivers

Cash And Short Term Investments12.9 M

Elicio Upcoming Events

15th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Elicio Therapeutics Financial Statements

Elicio Therapeutics investors use historical fundamental indicators, such as Elicio Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elicio Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue798.1 K816.3 K
Cost Of Revenue1.1 M1.1 M
Stock Based Compensation To Revenue 0.03  0.02 
Sales General And Administrative To Revenue 0.31  0.29 
Research And Ddevelopement To Revenue 0.57  0.54 
Capex To Revenue 0.02  0.02 
Revenue Per Share 10.17  9.67 
Ebit Per Revenue(1.03)(1.09)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CSXCSX Corporation
ETONEton Pharmaceuticals
ALLTAllot Communications

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY